May 16th 2024
Data from a meta-analysis of evinacumab trials reveal significant reductions in cholesterol and other lipid markers among patients with dyslipidemia.
Future Therapies in Lipidology
April 7th 2021In this portion of the panel discussion, panelists examine newer therapies for the treatment of lipid disorders. Included in this section are brief discussions around icosapent ethyl, inclisiran, and bempedoic acid. *This conversation occurred in February 2021 and regulatory approvals/decisions may have changed since filming.
Rosuvastatin/Ezetimibe Combination Therapy Approved for Lowering LDL-C
April 5th 2021Althera Pharmaceuticals announced the FDA approved rosuvastatin and ezetimibe (Roszet) as an adjunct to diet for lowering LDL-C in adults patients with primary non-familial hyperlipidemia or homozygous familial hypercholesterolemia.
Transgender Youth at Risk of Adverse Cardiometabolic Health, ENDO 2021 Study Finds
March 22nd 2021An analysis comparing propensity-matched data from 4k transgender is providing an updated overview of the risk profile for patients undergoing gender-affirming therapy compared to their cisgender counterparts.
Evinacumab (Evkeeza) Receives FDA Approval as Adjunct Therapy for HoFH
February 11th 2021A statement from Regeneron announced their ANGPTL3 inhibitor evinacumab (Evkeeza) received approval as an adjunct therapy for lowering LDL-C in patients 12 years and older with homozygous familial hypercholesterolemia.